Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.

Karin Berger, Dorothee Schopohl, Georg Wittmann, Wolfgang Schramm, Helmut Ostermann, Christina Rieger
Author Information
  1. Karin Berger: Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.
  2. Dorothee Schopohl: Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.
  3. Georg Wittmann: Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital of Munich, Munich, Germany.
  4. Wolfgang Schramm: University of Munich, Rudolf-Marx-Foundation, Munich, Germany.
  5. Helmut Ostermann: Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.
  6. Christina Rieger: Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.

Abstract

BACKGROUND: In Germany, about 60% of all produced platelet concentrates (PCs) are apheresis PCs (APCs). Ongoing discussions on APC reimbursement and costs might lead to a potential shift in pooled PC (PPC)/APC production. Objective of this analysis was to build a comprehensive model from the societal perspective to evaluate consequences associated with shifts in platelet supply and demand.
METHODS: Literature search, desktop researches on platelet supply and demand. Model calculations, time horizon one year: model input from the Paul-Ehrlich-Institute, data 2013. Base case: 19.2% of annual whole blood donations (WBDs) were used for production of 38.5% PPCs, decay of 46,218 PCs (8.0%). Scenarios calculated: variation in PPC proportion of 10-100%.
RESULTS: Base case: during PPC production 41,957-83,913 red blood cell concentrates (RBCCs) are estimated to be lost, which corresponds to 1-2% of annual RBCCs in Germany. Scenarios were calculated for a production of 60-100% PPCs: loss is estimated to be 1.5-5.0% of annual RBCCs (65,430-218,099), decay 54,189-69,022 PCs (9.4-12.0%).
CONCLUSION: Production of different blood components is interlinked and sensitive to unidimensional decisions. Increasing PPC proportion has negative impact on the RBCC production and on the antigen-matched APC donor pool. Completion of the model calculations to predict the optimal PPC/APC proportion would require evidence on the number of refractory patients, donor pool sizes, and incidences of diseases requiring platelet transfusions.

Keywords

References

  1. J Paediatr Child Health. 2012 Sep;48(9):816-22 [PMID: 22970675]
  2. Transfus Med Hemother. 2010 Jun;37(3):131-139 [PMID: 20737016]
  3. Hematology Am Soc Hematol Educ Program. 2007;:172-8 [PMID: 18024626]
  4. Clin Lab. 2015;61(7):869-75 [PMID: 26299092]
  5. Onkologie. 2010;33 Suppl 7:19-24 [PMID: 20926910]
  6. Transfus Med Hemother. 2010 Jun;37(3):155-159 [PMID: 20737019]
  7. Vox Sang. 2010 Oct;99(3):295-6; author reply 297-8 [PMID: 20561324]
  8. Vox Sang. 2011 Jan;100(1):10-21 [PMID: 21175652]
  9. Br J Haematol. 2008 Jul;142(3):348-60 [PMID: 18510692]
  10. Curr Opin Anaesthesiol. 2015 Jun;28(3):356-63 [PMID: 25827281]
  11. Pediatrics. 2014 Apr;133(4):715-21 [PMID: 24590747]
  12. Bone Marrow Transplant. 2007 Sep;40(5):461-4 [PMID: 17589530]
  13. N Engl J Med. 1997 Dec 25;337(26):1861-9 [PMID: 9417523]
  14. Transfus Med. 2014 Aug;24(4):213-8 [PMID: 24957661]
  15. Transfus Med Hemother. 2008 Apr;35(2):106-13 [PMID: 21512637]
  16. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Oct;58(10 ):1129-50 [PMID: 26411733]
  17. Tissue Antigens. 2012 Apr;79(4):237-45 [PMID: 22385314]
  18. Clin Lab. 2013;59(1-2):1-22 [PMID: 23505902]
  19. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Aug;55(8):914-22 [PMID: 22842884]
  20. Transfus Med Hemother. 2012 Apr;39(2):129-138 [PMID: 22670131]
  21. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Oct;58(10 ):1126-8 [PMID: 26411732]
  22. Vox Sang. 2010 Jul 1;99(1):1-15 [PMID: 20059760]

Word Cloud

Created with Highcharts 10.0.0productionplateletPCsPPCbloodconcentratesmodelannual0%proportionRBCCspoolplateletsGermanyAPCsupplydemandcalculationsBasecase:decayScenarioscellestimateddonorApheresisPooledBACKGROUND:60%producedapheresisAPCsOngoingdiscussionsreimbursementcostsmightleadpotentialshiftpooledPC/APCObjectiveanalysisbuildcomprehensivesocietalperspectiveevaluateconsequencesassociatedshiftsMETHODS:LiteraturesearchdesktopresearchesModeltimehorizononeyear:inputPaul-Ehrlich-Institutedata2013192%wholedonationsWBDsused385%PPCs462188calculated:variation10-100%RESULTS:41957-83913redlostcorresponds1-2%calculated60-100%PPCs:loss15-565430-21809954189-6902294-12CONCLUSION:ProductiondifferentcomponentsinterlinkedsensitiveunidimensionaldecisionsIncreasingnegativeimpactRBCCantigen-matchedCompletionpredictoptimalPPC/APCrequireevidencenumberrefractorypatientssizesincidencesdiseasesrequiringtransfusionsBloodProductSupplyGermany:ImpactPlateletConcentratesAntigen-matchedDonorRed

Similar Articles

Cited By